

Survey Data 2013 – 2017

Abstract

The rates of non-response for ANZDATA survey items over the last 5 years

anzdata@anzdata.org.au www.anzdata.org.au



The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Table 1 Demographics

Variable	2013	2014	2015	2016	2017
Frequency	3194	3345	3324	3485	3687
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	37 (1.2%)	51 (1.5%)	79 (2.4%)	122 (3.5%)	72 (2.0%)
Late referral seen <3 mths before 1st treatment	31 (1.0%)	74 (2.2%)	140 (4.2%)	173 (5.0%)	90 (2.4%)
Racial origin	22 (0.7%)	64 (1.9%)	106 (3.2%)	196 (5.6%)	79 (2.1%)
Primary renal disease	7 (0.2%)	32 (1.0%)	120 (3.6%)	165 (4.7%)	93 (2.5%)
Was native kidney biopsied?	40 (1.3%)	70 (2.1%)	137 (4.1%)	235 (6.7%)	128 (3.5%)
Serum creatinine at entry	34 (1.1%)	78 (2.3%)	139 (4.2%)	161 (4.6%)	114 (3.1%)
Height at RRT entry (cm)	42 (1.3%)	103 (3.1%)	140 (4.2%)	228 (6.5%)	166 (4.5%)
Weight at RRT entry (kg)	28 (0.9%)	54 (1.6%)	78 (2.3%)	143 (4.1%)	81 (2.2%)
Smoking status at RRT entry	23 (0.7%)	18 (0.5%)	140 (4.2%)	211 (6.1%)	149 (4.0%)

Table 2 Comorbidities at RRT entry

Variable	2013	2014	2015	2016	2017
Frequency	3194	3345	3324	3485	3687
Postcode	548 (17.2%)	533 (15.9%)	406 (12.2%)	208 (6.0%)	82 (2.2%)
Chronic lung disease	7 (0.2%)	19 (0.6%)	36 (1.1%)	94 (2.7%)	70 (1.9%)
Coronary artery disease	6 (0.2%)	20 (0.6%)	37 (1.1%)	95 (2.7%)	69 (1.9%)
Peripheral vascular disease	6 (0.2%)	19 (0.6%)	38 (1.1%)	94 (2.7%)	73 (2.0%)
Cerebrovascular disease	6 (0.2%)	18 (0.5%)	37 (1.1%)	92 (2.6%)	71 (1.9%)
Diabetes	6 (0.2%)	17 (0.5%)	31 (0.9%)	85 (2.4%)	54 (1.5%)

Table 3 Comorbidities at survey date

Variable	2013	2014	2015	2016	2017
Frequency	28704	29830	30847	31886	33086
Postcode	4784 (16.7%)	4937 (16.6%)	3117 (10.1%)	1232 (3.9%)	442 (1.3%)
Chronic lung disease	69 (0.2%)	89 (0.3%)	144 (0.5%)	173 (0.5%)	170 (0.5%)
Coronary artery disease	68 (0.2%)	88 (0.3%)	143 (0.5%)	176 (0.6%)	166 (0.5%)
Peripheral vascular disease	68 (0.2%)	88 (0.3%)	142 (0.5%)	174 (0.5%)	172 (0.5%)
Cerebrovascular disease	72 (0.3%)	90 (0.3%)	144 (0.5%)	177 (0.6%)	170 (0.5%)
Diabetes	72 (0.3%)	95 (0.3%)	157 (0.5%)	178 (0.6%)	147 (0.4%)
Hepatitis C Antibody	59 (0.2%)	84 (0.3%)	189 (0.6%)	314 (1.0%)	275 (0.8%)



Table 4 Reason for change from CAPD to APD

Variable	2013	2014	2015	2016	2017
Frequency	611	658	700	608	599
Reason transfer from dialysis during survey	62 (10.1%)	49 (7.4%)	51 (7.3%)	70 (11.5%)	70 (11.7%)

Table 5 Reason for change from APD to CAPD

Variable	2013	2014	2015	2016	2017
Frequency	135	114	127	119	138
Reason transfer from dialysis during survey	15 (11.1%)	10 (8.8%)	14 (11.0%)	21 (17.6%)	17 (12.3%)

Table 6 Reason for change from PD to HD

Variable	2013	2014	2015	2016	2017
Frequency	755	731	842	834	795
Reason transfer from dialysis during survey	42 (5.6%)	49 (6.7%)	77 (9.1%)	105 (12.6%)	61 (7.7%)

Table 7 Reason for change from HD to PD

Variable	2013	2014	2015	2016	2017
Frequency	600	582	546	537	539
Reason transfer from dialysis during survey	36 (6.0%)	49 (8.4%)	49 (9.0%)	87 (16.2%)	53 (9.8%)

Table 8 Cause of death

Variable	2013	2014	2015	2016	2017
Frequency	2226	2299	2433	2541	2573
Cause of death	0 (0.0%)	0 (0.0%)	2 (0.1%)	21 (0.8%)	97 (3.8%)

Table 9 Dialysis data

Variable	2013	2014	2015	2016	2017
Frequency	17409	18011	18497	18959	19372
Dialysis type	188 (1.1%)	298 (1.7%)	258 (1.4%)	160 (0.8%)	6 (0.0%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	390 (2.2%)	790 (4.4%)	1146 (6.2%)	1617 (8.5%)	906 (4.7%)
Uncorrected calcium levels (mmol/l)	430 (2.5%)	715 (4.0%)	1113 (6.0%)	1489 (7.9%)	827 (4.3%)
Phosphate levels (mmol/l)	416 (2.4%)	650 (3.6%)	1053 (5.7%)	1461 (7.7%)	808 (4.2%)
Haemoglobin level nearest end Survey (g/l)	431 (2.5%)	639 (3.5%)	1046 (5.7%)	1456 (7.7%)	822 (4.2%)
EPO Agent	418 (2.4%)	628 (3.5%)	1026 (5.5%)	1495 (7.9%)	855 (4.4%)
Ferritin within last 3 months of Survey	1398 (8.0%)	1587 (8.8%)	1867 (10.1%)	2624 (13.8%)	1884 (9.7%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	1885 (10.8%)	2105 (11.7%)	2360 (12.8%)	3256 (17.2%)	2270 (11.7%)



Table 10 Haemodialysis data

Variable	2013	2014	2015	2016	2017
Frequency	14069	14453	14860	15323	15707
Dialyser brand, model, membrane, surface area	317 (2.3%)	611 (4.2%)	943 (6.3%)	1035 (6.8%)	726 (4.6%)
Blood flow rate (mls/min)	310 (2.2%)	622 (4.3%)	941 (6.3%)	1311 (8.6%)	726 (4.6%)
Frequency of dialysis per week	306 (2.2%)	600 (4.2%)	925 (6.2%)	1285 (8.4%)	701 (4.5%)
Hours per session	307 (2.2%)	604 (4.2%)	929 (6.3%)	1305 (8.5%)	724 (4.6%)
Adequacy method (urea reduction or Kt/V)	2384 (16.9%)	2588 (17.9%)	2793 (18.8%)	3493 (22.8%)	2855 (18.2%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	2396 (17.0%)	2690 (18.6%)	2826 (19.0%)	3378 (22.0%)	2876 (18.3%)
Vascular access in use at last haemodialysis	303 (2.2%)	652 (4.5%)	1008 (6.8%)	1348 (8.8%)	748 (4.8%)

Table 11 Access at first HD

Variable	2013	2014	2015	2016	2017
Frequency	2634	2672	2727	2878	3040
Vascular access in use at first haemodialysis	84 (3.2%)	148 (5.5%)	246 (9.0%)	261 (9.1%)	125 (4.1%)

Table 12 Peritoneal dialysis data

Variable	2013	2014	2015	2016	2017
Frequency	4412	4627	4766	4773	4759
Type of Peritoneal Connection System	142 (3.2%)	213 (4.6%)	394 (8.3%)	401 (8.4%)	272 (5.7%)
Total volume weekly exchanges - All PD	151 (3.4%)	218 (4.7%)	365 (7.7%)	560 (11.7%)	265 (5.6%)
PD Solution Glucose	138 (3.1%)	198 (4.3%)	348 (7.3%)	436 (9.1%)	253 (5.3%)
PD Solution Iodextrin	138 (3.1%)	201 (4.3%)	354 (7.4%)	434 (9.1%)	254 (5.3%)
PD Solution Low GDP (either Lactate or Bicarbonate)	138 (3.1%)	207 (4.5%)	369 (7.7%)	435 (9.1%)	250 (5.3%)
Creatinine Clearance (litres per week)	1265 (28.7%)	1398 (30.2%)	1645 (34.5%)	1781 (37.3%)	1554 (32.7%)
Dialysate Only Weekly Kt/V value on PD	1264 (28.6%)	1403 (30.3%)	1647 (34.6%)	1781 (37.3%)	1543 (32.4%)
Residual renal function (creatinine clearance - GFR)	1295 (29.4%)	1441 (31.1%)	1703 (35.7%)	1815 (38.0%)	1589 (33.4%)

Table 13 Peritoneal dialysis PET test

Variable	2013	2014	2015	2016	2017
Frequency	1282	1382	1352	1382	1385
PET test for PD-within first 6 mths starting?	553 (43.1%)	1167 (84.4%)	1253 (92.7%)	1315 (95.2%)	1267 (91.5%)



Table 14 Peritonitis episodes data

Variable	2013	2014	2015	2016	2017
Frequency	1181	1116	1157	1091	1064
Was this a relapse or recurrence of peritonitis?	178 (15.1%)	195 (17.5%)	113 (9.8%)	150 (13.7%)	129 (12.1%)
Technique at time of infection	173 (14.6%)	190 (17.0%)	64 (5.5%)	62 (5.7%)	52 (4.9%)
Antifungal Therapy?	188 (15.9%)	228 (20.4%)	147 (12.7%)	182 (16.7%)	157 (14.8%)
Name of initial regimen first antibiotic given	172 (14.6%)	190 (17.0%)	122 (10.5%)	143 (13.1%)	129 (12.1%)
Name of final regimen first antibiotic given	219 (18.5%)	239 (21.4%)	154 (13.3%)	169 (15.5%)	183 (17.2%)
Glucose PD Solution at time of infection?	193 (16.3%)	215 (19.3%)	186 (16.1%)	200 (18.3%)	173 (16.3%)
Icodextrin PD Solution at time of infection?	196 (16.6%)	226 (20.3%)	191 (16.5%)	210 (19.2%)	175 (16.4%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	201 (17.0%)	232 (20.8%)	168 (14.5%)	197 (18.1%)	192 (18.0%)
Was patient hospitalised overnight?	182 (15.4%)	207 (18.5%)	128 (11.1%)	151 (13.8%)	127 (11.9%)
Was catheter removed?	179 (15.2%)	193 (17.3%)	118 (10.2%)	154 (14.1%)	128 (12.0%)
Did patient have interim haemodialysis?	193 (16.3%)	211 (18.9%)	131 (11.3%)	169 (15.5%)	142 (13.3%)
Did patient transfer to permanent haemodialysis?	194 (16.4%)	206 (18.5%)	127 (11.0%)	164 (15.0%)	146 (13.7%)

Table 15 Transplant baseline data

Variable	2013	2014	2015	2016	2017
Frequency	999	1041	1092	1257	1290
Recipient CMV antibody status	20 (2.0%)	41 (3.9%)	53 (4.9%)	135 (10.7%)	99 (7.7%)
Recipient EBV antibody status	20 (2.0%)	44 (4.2%)	59 (5.4%)	144 (11.5%)	97 (7.5%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	27 (2.7%)	72 (6.9%)	69 (6.3%)	150 (11.9%)	97 (7.5%)
Immediate function	19 (1.9%)	38 (3.7%)	43 (3.9%)	121 (9.6%)	64 (5.0%)
HLA-A mismatch	25 (2.5%)	35 (3.4%)	23 (2.1%)	24 (1.9%)	24 (1.9%)
HLA-B mismatch	27 (2.7%)	35 (3.4%)	22 (2.0%)	24 (1.9%)	24 (1.9%)
HLA-DR mismatch	38 (3.8%)	37 (3.6%)	22 (2.0%)	24 (1.9%)	24 (1.9%)
HLA-DQ mismatch	782 (78.3%)	691 (66.4%)	583 (53.4%)	568 (45.2%)	539 (41.8%)
Donor blood group	5 (0.5%)	7 (0.7%)	15 (1.4%)	10 (0.8%)	1 (0.1%)
Recipient blood group	3 (0.3%)	5 (0.5%)	13 (1.2%)	13 (1.0%)	0 (0.0%)
Maximum cytotoxic antibodies	116 (11.6%)	59 (5.7%)	74 (6.8%)	90 (7.2%)	121 (9.4%)
Current (At transplant) antibodies	170 (17.0%)	74 (7.1%)	72 (6.6%)	79 (6.3%)	68 (5.3%)



Table 16 Cause of graft failure

Variable	2013	2014	2015	2016	2017
Frequency	259	290	313	296	309
Cause of graft failure	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.7%)	36 (11.7%)

Table 17 Rejection data

Variable	2013	2014	2015	2016	2017
Frequency	422	469	480	423	535
Was a biopsy performed?	10 (2.4%)	13 (2.8%)	9 (1.9%)	5 (1.2%)	2 (0.4%)
Response of this rejection to treatment	13 (3.1%)	19 (4.1%)	20 (4.2%)	20 (4.7%)	40 (7.5%)
Primary treatment of rejection	5 (1.2%)	6 (1.3%)	6 (1.3%)	12 (2.8%)	10 (1.9%)

Table 18 Rejection data if biopsy performed

Variable	2013	2014	2015	2016	2017
Frequency	402	446	462	406	523
If biopsy is Yes ?Cellular	39 (9.7%)	30 (6.7%)	5 (1.1%)	9 (2.2%)	13 (2.5%)
If biopsy is Yes ?Glomerular	44 (10.9%)	46 (10.3%)	9 (1.9%)	13 (3.2%)	13 (2.5%)
If biopsy is Yes ?Vascular	47 (11.7%)	43 (9.6%)	8 (1.7%)	17 (4.2%)	20 (3.8%)
Humoral Rejection	42 (10.4%)	53 (11.9%)	15 (3.2%)	19 (4.7%)	13 (2.5%)
If biopsy is Yes and Banff g is known	60 (14.9%)	66 (14.8%)	58 (12.6%)	60 (14.8%)	39 (7.5%)
If biopsy is Yes and Banff i is known	60 (14.9%)	66 (14.8%)	58 (12.6%)	55 (13.5%)	38 (7.3%)
If biopsy is Yes and Banff t is known	60 (14.9%)	65 (14.6%)	57 (12.3%)	55 (13.5%)	38 (7.3%)
If biopsy is Yes and Banff v is known	61 (15.2%)	67 (15.0%)	60 (13.0%)	62 (15.3%)	47 (9.0%)

Table 19 Rejection data if biopsy not performed

Variable	2013	2014	2015	2016	2017
Frequency	10	10	9	12	10
Likelihood of rejection if biopsy not performed	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (8.3%)	0 (0.0%)

Table 20 Transplant follow-up data, 0 months

Variable	2013	2014	2015	2016	2017
Frequency	1009	1061	1111	1272	1303
Weight	29 (2.9%)	67 (6.3%)	61 (5.5%)	132 (10.4%)	80 (6.1%)
Drug data	13 (1.3%)	39 (3.7%)	43 (3.9%)	120 (9.4%)	65 (5.0%)



Table 21 Transplant follow-up data, 1 months

Variable	2013	2014	2015	2016	2017
Frequency	995	1036	1053	1261	1292
Weight	29 (2.9%)	57 (5.5%)	101 (9.6%)	138 (10.9%)	80 (6.2%)
Serum creatinine	18 (1.8%)	37 (3.6%)	46 (4.4%)	113 (9.0%)	79 (6.1%)
Drug data	11 (1.1%)	34 (3.3%)	39 (3.7%)	105 (8.3%)	46 (3.6%)

Table 22 Transplant follow-up data, 2 months

Variable	2013	2014	2015	2016	2017
Frequency	1008	1011	1061	1210	1298
Weight	33 (3.3%)	66 (6.5%)	116 (10.9%)	175 (14.5%)	118 (9.1%)
Serum creatinine	18 (1.8%)	41 (4.1%)	45 (4.2%)	131 (10.8%)	91 (7.0%)
Drug data	12 (1.2%)	36 (3.6%)	38 (3.6%)	124 (10.2%)	69 (5.3%)

Table 23 Transplant follow-up data, 3 months

Variable	2013	2014	2015	2016	2017
Frequency	994	1018	1053	1187	1290
Weight	37 (3.7%)	81 (8.0%)	125 (11.9%)	172 (14.5%)	179 (13.9%)
Serum creatinine	22 (2.2%)	49 (4.8%)	46 (4.4%)	115 (9.7%)	131 (10.2%)
Drug data	12 (1.2%)	44 (4.3%)	39 (3.7%)	110 (9.3%)	105 (8.1%)

Table 24 Transplant follow-up data, 6 months

Variable	2013	2014	2015	2016	2017
Frequency	1016	983	984	1183	1265
Weight	41 (4.0%)	93 (9.5%)	144 (14.6%)	222 (18.8%)	231 (18.3%)
Serum creatinine	20 (2.0%)	48 (4.9%)	58 (5.9%)	145 (12.3%)	148 (11.7%)
Drug data	7 (0.7%)	46 (4.7%)	54 (5.5%)	146 (12.3%)	151 (11.9%)

Table 25 Transplant follow-up data, 12 months

Variable	2013	2014	2015	2016	2017
Frequency	917	959	1005	1045	1211
Weight	44 (4.8%)	101 (10.5%)	136 (13.5%)	176 (16.8%)	186 (15.4%)
Serum creatinine	13 (1.4%)	33 (3.4%)	46 (4.6%)	120 (11.5%)	132 (10.9%)
Drug data	6 (0.7%)	36 (3.8%)	44 (4.4%)	111 (10.6%)	123 (10.2%)



Table 26 Transplant follow-up data, 24 months

Variable	2013	2014	2015	2016	2017
Frequency	898	895	937	987	1014
Weight	46 (5.1%)	96 (10.7%)	115 (12.3%)	163 (16.5%)	157 (15.5%)
Serum creatinine	25 (2.8%)	27 (3.0%)	48 (5.1%)	89 (9.0%)	112 (11.0%)
Drug data	8 (0.9%)	33 (3.7%)	48 (5.1%)	86 (8.7%)	108 (10.7%)

Table 27 Transplant follow-up data, 36 months

Variable	2013	2014	2015	2016	2017
Frequency	854	859	870	902	952
Weight	44 (5.2%)	91 (10.6%)	116 (13.3%)	130 (14.4%)	155 (16.3%)
Serum creatinine	20 (2.3%)	35 (4.1%)	42 (4.8%)	84 (9.3%)	99 (10.4%)
Drug data	6 (0.7%)	40 (4.7%)	42 (4.8%)	83 (9.2%)	93 (9.8%)

Table 28 Transplant follow-up data, 60 months

Variable	2013	2014	2015	2016	2017
Frequency	766	783	798	806	810
Weight	30 (3.9%)	98 (12.5%)	127 (15.9%)	165 (20.5%)	147 (18.1%)
Serum creatinine	15 (2.0%)	34 (4.3%)	44 (5.5%)	104 (12.9%)	84 (10.4%)
Drug data	3 (0.4%)	41 (5.2%)	38 (4.8%)	95 (11.8%)	82 (10.1%)

Table 29 Transplant follow-up data, 84 months

Variable	2013	2014	2015	2016	2017
Frequency	570	589	701	721	738
Weight	34 (6.0%)	68 (11.5%)	91 (13.0%)	146 (20.2%)	128 (17.3%)
Serum creatinine	21 (3.7%)	20 (3.4%)	40 (5.7%)	94 (13.0%)	86 (11.7%)
Drug data	6 (1.1%)	24 (4.1%)	39 (5.6%)	82 (11.4%)	81 (11.0%)

Table 30 Transplant follow-up data, 120 months

Variable	2013	2014	2015	2016	2017
Frequency	426	521	471	492	493
Weight	25 (5.9%)	53 (10.2%)	58 (12.3%)	93 (18.9%)	73 (14.8%)
Serum creatinine	11 (2.6%)	13 (2.5%)	31 (6.6%)	57 (11.6%)	47 (9.5%)
Drug data	3 (0.7%)	4 (0.8%)	31 (6.6%)	49 (10.0%)	50 (10.1%)



Table 31 Transplant follow-up data, 180 months

Variable	2013	2014	2015	2016	2017
Frequency	278	258	323	305	367
Weight	26 (9.4%)	36 (14.0%)	45 (13.9%)	66 (21.6%)	54 (14.7%)
Serum creatinine	12 (4.3%)	13 (5.0%)	22 (6.8%)	45 (14.8%)	35 (9.5%)
Drug data	3 (1.1%)	11 (4.3%)	25 (7.7%)	43 (14.1%)	41 (11.2%)

Table 32 Transplant follow-up data, 240 months

Variable	2013	2014	2015	2016	2017
Frequency	120	138	163	181	196
Weight	9 (7.5%)	15 (10.9%)	25 (15.3%)	29 (16.0%)	37 (18.9%)
Serum creatinine	4 (3.3%)	7 (5.1%)	12 (7.4%)	18 (9.9%)	26 (13.3%)
Drug data	1 (0.8%)	7 (5.1%)	12 (7.4%)	19 (10.5%)	29 (14.8%)

Table 33 Transplant follow-up data, 300 months

Variable	2013	2014	2015	2016	2017
Frequency	84	82	84	97	93
Weight	6 (7.1%)	8 (9.8%)	14 (16.7%)	17 (17.5%)	18 (19.4%)
Serum creatinine	2 (2.4%)	3 (3.7%)	11 (13.1%)	9 (9.3%)	10 (10.8%)
Drug data	0 (0.0%)	3 (3.7%)	5 (6.0%)	8 (8.2%)	14 (15.1%)

Table 34 Transplant follow-up data, 360 months

Variable	2013	2014	2015	2016	2017
Frequency	39	41	39	46	44
Weight	3 (7.7%)	10 (24.4%)	9 (23.1%)	11 (23.9%)	9 (20.5%)
Serum creatinine	2 (5.1%)	4 (9.8%)	4 (10.3%)	7 (15.2%)	8 (18.2%)
Drug data	0 (0.0%)	4 (9.8%)	3 (7.7%)	8 (17.4%)	5 (11.4%)

Table 35 Transplant follow-up data, 420 months

Variable	2013	2014	2015	2016	2017
Frequency	20	20	19	30	28
Weight	2 (10.0%)	4 (20.0%)	5 (26.3%)	10 (33.3%)	7 (25.0%)
Serum creatinine	1 (5.0%)	2 (10.0%)	2 (10.5%)	6 (20.0%)	4 (14.3%)
Drug data	0 (0.0%)	4 (20.0%)	2 (10.5%)	6 (20.0%)	4 (14.3%)



Table 36 Transplant follow-up data, 480 months

Variable	2013	2014	2015	2016	2017
Frequency	4	9	7	9	15
Weight	1 (25.0%)	3 (33.3%)	1 (14.3%)	1 (11.1%)	2 (13.3%)
Serum creatinine	1 (25.0%)	2 (22.2%)	0 (0.0%)	0 (0.0%)	1 (6.7%)
Drug data	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 37 Transplant follow-up data, 540 months

Variable	2013	2014	2015	2016	2017
Frequency	2	2	5	6	0
Weight	2 (100.0%)	1 (50.0%)	3 (60.0%)	2 (33.3%)	-
Serum creatinine	2 (100.0%)	0 (0.0%)	1 (20.0%)	2 (33.3%)	-
Drug data	2 (100.0%)	0 (0.0%)	1 (20.0%)	2 (33.3%)	-

Table 38 Paediatric assessment at entry

Variable	2013	2014	2015	2016	2017
Frequency	39	43	36	40	45
Height	12 (30.8%)	3 (7.0%)	7 (19.4%)	17 (42.5%)	18 (40.0%)
Weight	11 (28.2%)	3 (7.0%)	7 (19.4%)	17 (42.5%)	18 (40.0%)
Paediatric Assessment at end of each Survey	13 (33.3%)	3 (7.0%)	9 (25.0%)	18 (45.0%)	19 (42.2%)

Table 39 Paediatric assessment at survey

Variable	2013	2014	2015	2016	2017
Frequency	331	338	331	339	351
Height	32 (9.7%)	30 (8.9%)	26 (7.9%)	25 (7.4%)	44 (12.5%)
Weight	26 (7.9%)	21 (6.2%)	21 (6.3%)	23 (6.8%)	44 (12.5%)
Paediatric Assessment at end of each Survey	25 (7.6%)	20 (5.9%)	24 (7.3%)	25 (7.4%)	45 (12.8%)

Table 40 Parenthood data

Variable	2013	2014	2015	2016	2017
Frequency	65	70	74	52	58
Pregnancy outcome	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
Foetal outcome	7 (10.8%)	2 (2.9%)	9 (12.2%)	16 (30.8%)	44 (75.9%)
Neonatal survival	6 (9.2%)	4 (5.7%)	8 (10.8%)	13 (25.0%)	8 (13.8%)
Medical conditions acquired	4 (6.2%)	2 (2.9%)	5 (6.8%)	7 (13.5%)	43 (74.1%)



Table 41 Parenthood birthweight data

Variable	2013	2014	2015	2016	2017
Frequency	51	62	68	42	53
Weight at birth (gms)	14 (27.5%)	15 (24.2%)	18 (26.5%)	8 (19.0%)	9 (17.0%)

Table 42 Parenthood creatinine prior to conception

Variable	2013	2014	2015	2016	2017
Frequency	22	27	20	15	18
Creatinine prior to conception (umol/L)	5 (22.7%)	2 (7.4%)	3 (15.0%)	2 (13.3%)	2 (11.1%)

Table 43 Parenthood creatinine post delivery

Variable	2013	2014	2015	2016	2017
Frequency	21	27	19	15	14
Creatinine 3 months post delivery (umol/L)	8 (38.1%)	4 (14.8%)	5 (26.3%)	2 (13.3%)	2 (14.3%)

Table 44 Non-skin cancer data

Variable	2013	2014	2015	2016	2017
Frequency	668	603	594	529	444
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	6 (0.9%)	14 (2.3%)	11 (1.9%)	8 (1.5%)	9 (2.0%)
Cancer staging code	12 (1.8%)	14 (2.3%)	22 (3.7%)	24 (4.5%)	32 (7.2%)
Type 1st treatment	15 (2.2%)	11 (1.8%)	27 (4.5%)	28 (5.3%)	36 (8.1%)